Zoledronic acid produces antitumor effects on mesothelioma through apoptosis and S-Phase arrest in p53-Independent and ras prenylation-independent manners

Journal of Thoracic Oncology

Volumn 7, Issue 5, 2012, Pages 873-882

  Okamoto, Shinya ^a   Kawamura, Kiyoko ^b   Li, Quanhai ^b   Yamanaka, Makako ^b,c   Yang, Shan ^b   Fukamachi, Toshihiko ^a   Tada, Yuji ^c   Tatsumi, Koichiro ^c   Shimada, Hideaki ^d   Hiroshima, Kenzo ^e   Kobayashi, Hiroshi ^a   Tagawa, Masatoshi ^b  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA CANCER CENTER   (Japan)

^c CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Tokyo Women s Medical University   (Japan)

Author keywords

Bisphosphonate; Mesothelioma; P53; Prenylation; Small G protein

Indexed keywords

CASPASE; GERANYLGERANYL PYROPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P53; RAS PROTEIN; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MESOTHELIOMA; MOUSE; NONHUMAN; PRENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84862123295     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31824c7d43     Document Type: Article

References (45)

1. Tada Y, Takiguchi Y, Hiroshima K,. et al. Gene therapy for malignant pleural mesothelioma: present and future. Oncol Res 2008;17:239-246.
2. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-1603.
3. Hopkins-Donaldson S, Belyanskaya LL, Simões-Wüst AP,. et al. p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma. Neoplasia 2006;8:551-559.
4. Prins JB, Williamson KA, Kamp MM,. et al. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 1998;75:649-653.
5. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408.
6. Vogelzang NJ, Rusthoven JJ, Symanowski J,. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
7. Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T. Zoledronic acid - a multiplicity of anti-cancer action. Curr Med Chem 2007;14:2126-2135.
8. Green JR. Bisphosphonates: preclinical review. Oncologist 2004;9 Suppl 4:3-13.
9. Green JR. Antitumor effects of bisphosphonates. Cancer 2003;97 (3 Suppl):840-847.
10. Kawata E, Ashihara E, Nakagawa Y,. et al. A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro. Cancer Lett 2010;294:245-253.
11. Kuroda J, Kimura S, Segawa H,. et al. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 2003;102:2229-2235.
12. Koshimune R, Aoe M, Toyooka S,. et al. Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines. BMC Cancer 2007;7.
13. Nakataki E, Yano S, Matsumori Y,. et al. Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. Cancer Sci 2006;97:183-191.
14. Tassone P, Tagliaferri P, Viscomi C,. et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 2003;88:1971-1978.
15. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-1783.
16. Liebermann DA, Hoffman B, Vesely D. p53 induced growth arrest versus apoptosis and its modulation by survival cytokines. Cell Cycle 2007;6:166-170.
17. Pochampally R, Fodera B, Chen L, Lu W, Chen J. Activation of an MDM2-specific caspase by p53 in the absence of apoptosis. J Biol Chem 1999;274:15271-15277.
18. Petitjean A, Mathe E, Kato S,. et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-629.
19. Jänne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 2002;62:5242-5247.
20. Pang L, Sawada T, Decker SJ, Saltiel AR. Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem 1995;270:13585-13588.
21. Ory B, Blanchard F, Battaglia S, Gouin F, Rédini F, Heymann D. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol 2007;71:333-343.
22. Kuroda J, Kimura S, Segawa H,. et al. p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid. Cancer Sci 2004;95:186-192.
23. Benassi MS, Chiechi A, Ponticelli F,. et al. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Lett 2007;250:194-205.
24. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009;137:609-622.
25. Westwood G, Dibling BC, Cuthbert-Heavens D, Burchill SA. Basic fibroblast growth factor (bFGF)-induced cell death is mediated through a caspase-dependent and p53-independent cell death receptor pathway. Oncogene 2002;21:809-824.
26. Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. J Cell Sci 2005;118(Pt 5):843-846.
27. Appels NM, Beijnen JH, Schellens JH. Development of farnesyl transferase inhibitors: a review. Oncologist 2005;10:565-578.
28. Wright LP Philips MR. Thematic review series: lipid posttranslational modifications. CAAX modification and membrane targeting of Ras. J Lipid Res 2006;47:883-891.
29. Iguchi T, Miyakawa Y, Yamamoto K, Kizaki M, Ikeda Y. Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cell Signal 2003;15:719-727.
30. Wakchoure S, Merrell MA, Aldrich W,. et al. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res 2006;12:2862-2868.
31. Romani AA, Desenzani S, Morganti MM, La Monica S, Borghetti AF, Soliani P. Zoledronic acid determines S-phase arrest but fails to induce apoptosis in cholangiocarcinoma cells. Biochem Pharmacol 2009;78:133-141.
32. Räikkönen J, Mönkkönen H, Auriola S, Mönkkönen J. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells. Biochem Pharmacol 2010;79:777-783.
33. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004;10:4559-4567.
34. Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998;58:5294-5297.
35. Bar-Sagi D Hall A. Ras and Rho GTPases: a family reunion. Cell 2000;103:227-238.
36. Tang D, Lahti JM, Kidd VJ. Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporine-mediated apoptosis. J Biol Chem 2000;275:9303-9307.
37. Engels IH, Stepczynska A, Stroh C,. et al. Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene 2000;19:4563-4573.
38. Iguchi T, Miyakawa Y, Saito K,. et al. Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells. Int J Oncol 2007;31:285-291.
39. Roelofs AJ, Hulley PA, Meijer A, Ebetino FH, Russell RG, Shipman CM. Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells. Int J Cancer 2006;119:1254-1261.
40. Merrell MA, Wakchoure S, Ilvesaro JM,. et al. Differential effects of Ca(2+) on bisphosphonate-induced growth inhibition in breast cancer and mesothelioma cells. Eur J Pharmacol 2007;559:21-31.
41. Skerjanec A, Berenson J, Hsu C,. et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003;43:154-162.
42. Sato M, Grasser W, Endo N,. et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-2105.
43. Sandler ED, Hattner RS, Parisi MT, Miller TR. Clinical utility of bone scan features of pleural effusion: sensitivity and specificity for malignancy based on pleural fluid cytopathology. J Nucl Med 1994;35:429-431.
44. Raizon A, Schwartz A, Hix W, Rockoff SD. Calcification as a sign of sarcomatous degeneration of malignant pleural mesotheliomas: a new CT finding. J Comput Assist Tomogr 1996;20:42-44.
45. Todaro M, D'Asaro M, Caccamo N,. et al. Efficient killing of human colon cancer stem cells by .d T lymphocytes. J Immunol 2009; 182:7287-7296.